Drug-eluting Stents for Patients with Acute Coronary Syndromes: an Analysis of Long Term Outcome

Yanlin LI,Haiming SHI,Xinping LUO,Ben-Dor Itsik,Torguson Rebecca,Xue Zhenyi,Lindsay Joseph,D. Augusto,Waksman Ron
2010-01-01
Abstract:Objective To determine whether drug-eluting stents (DES) have similar advantages over bare-metal stents (BMS) for patients with acute coronary syndromes (ACS),smilar to the situation for patient with stable angina pectoris. Methods From Jan. 2000 to Dec. 2007,a cohort of 3 771 patients underwent selective percutaneous coronary intervention with stent implantation in native coronary arteries. Patients were classified as having stable or unstable symptoms on presentation and then further divided according to stent types,DES or bare-metal stent. The end point consisted of death,myocardial infarction and target vessel revascularization (TVR) 1 year after treatment. Results BMS and DES led to no difference in total mortality or Q-wave MI 1 year after treatment in both stable and unstable groups. There were significantly less TVR events after DES implantation than after BMS for the stable patients (5.6% vs. 11.4%,P0.01); this benefit was not found in patients with unstable symptoms (8.0% vs. 7.2%,P0.05). Stent thrombosis was rarely seen in all stent type groups. Conclusion DES can greatly reduce the TVR in patients with stable angina pectoris,but not in patient with ACS,which may be due to the more frequent presence of vulnerable plaques in patients with ACS.
What problem does this paper attempt to address?